BioSpace News Archive

Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company plans to participate in several upcoming events:

MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostics designed to provide physicians with clinically actionable information to improve the patient outcomes, announces that President and CEO Michael Nall will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time).

Diversity of Experience Brings New Insight and Proven Leadership to Support Advanced Commercial Structure While Balancing Continuity in Key Positions Molly Henderson Named Chief Financial Officer Jason Smith Named General Counsel and Chief Compliance Officer Polly A. Murphy, DVM, Ph.D., Named Chief Business Officer PRINCETON, N.J.--( BUSINESS WIRE )-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedica

AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Th

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced the appointment of Dean J. Mitchell as board Chairman. Mr. Mitchell is an accomplished executive who brings more than three decades of experience in the biophar

Initial presentation of data from the Phase 1b part of the LIO-1 trial of lucitanib in combination with nivolumab in advanced metastatic solid tumors New data analyses for Rubraca ® (rucaparib) from the Phase 2 TRITON2 and Phase 3 ARIEL3 studies in patients with metastatic castration-resistant prostate cancer (mCRPC) and recurrent ovarian cancer, respectively First presentation of preclinical data for FAP-2286, a novel peptide-targeted

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference

Parvizi Surgical Innovation, LLC (PSI) is pleased to announce an investment and partnership with Coracoid Solutions, LLC (CCS), an early-stage medical device company focused on sports medicine procedures.